Cerebrospinal fluid (CSF), with its protein markers, is a formidable material for investigating the relationships among the various cell types involved during the initial phase of plaque formation, or, successively, in the remyelination process. Its analysis may give definite help in better focusing on therapeutic objectives and therapeutic tools. Therefore, the possible use of CSF MBP, S-100, GFAP, N-CAM, NGF, and CNTF in pathogenetic studies and in clinical follow-up is critically reviewed. The need for correct interpretation of the data, for uniformity and reliability of the analytical methods, and for easy access to them is stressed. CSF examination and MRI should not be considered as alternative tools, or in competition, but should be used together, to take the maximum advantage of their individual possibilities.
Massaro AR. (1992) Notes on the therapy of multiple sclerosis . It J Neurol SciS14: 137-143 .
2.
Miller DHet al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis . Ann Neurol39: 6-16 .
3.
Filippi Met al. (1995) A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis . Neurology45: 478-482 .
4.
Arnold DLet al. (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques . Ann Neurol31: 235-241 .
5.
Massaro ARet al. (1985) Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase . It J Neurol Sci6: 53-56 .
6.
Massaro AR , Scivoletto G , Tonali P. (1990) Cerebrospinal fluid markers in neurological disorders . It J Neurol Sci11: 537-547 .
7.
Massaro AR , Carnevale A , Tonali P , Bock E. (1997) Glial cell pathobiology in multiple sclerosis detected by CSF markers. In: Teelken AW , Korf J , eds. Neurochemistry. New York: Plenum PC . pp. 451-455.
8.
Massaro AR , Albrechtsen M , Carbone G , Bock E. (1987) Cerebrospinal fluid markers in multiple sclerosis. In: Serlupi-Crescenzi G , ed. A Multidisciplinary Approach to Myelin Disease. New York: Plenum PC pp. 267-274.
9.
Massaro AR. (in press) La sclerosi multipla. In: Bergonzi P , Massaro AR , eds. Trattato Italiano di Neurologia, vol. 4. Roma: Verduci Editore .
10.
Massaro AR , Albrechtsen M , Bock E. (1987) N-CAM in CSF: a marker of synaptic remodelling after acute phases of multiple sclerosis?It J Neurol SciS6: 85-88 .
11.
Massaro AR , Albrechtsen M , Bock E. (1987) Determination of the neural-cell adhesion molecule (N-CAM) in cerebrospinal fluid from patients with multiple sclerosis. In: Lowenthal A , Raus J , eds. Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. New York: Plenum PC pp. 397-402.
12.
Bath S , Silberberg DH. (1986) Oligodendrocyte cell adhesion molecules are related to N-CAM . J Neurosci6: 3348-3354 .
13.
Bath S , Silberberg DH. (1988) N-CAM 180, the largest component of the N-CAM, is reduced in dysmyelinating quaking mutant mouse brain . Brain Res452: 373-377 .
14.
Bath S , Silberberg DH. (1988) Developmental expression of N-CAM of oligodendrocytes in vivo and in culture . J Neurochem50: 1830-1838 .
15.
Louis J-C , Magal E , Takayama S , Varon S. (1993) CNTF protection of oligodendrocytes against natural and tumor necrosis factor induced death . Science259: 689-692 .
16.
D'Souza S , Alinauskas K , Antel JP. (1996) Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury . J Neurosci Res43: 289-298 .
17.
Massaro AR , Soranzo C , Carnevale A. (1997) Cerebrospinal fluid ciliary neurotrophic factor (CNTF) in neurological patients . Europ Neurol37: 243-246 .
18.
Massaro ARet al. (1997) Neurotrophic factors in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. In: Abramski O , Ovadia H , eds. Frontiers in Multiple Sclerosis. London: Martin Dunitz Publisher pp. 155-160.
19.
Whitaker JN. (1977) Myelin encephalitogenic protein fragments in CSF of persons with multiple sclerosis . Neurology27: 911-920 .
20.
Cohen SRet al. (1980) A diagnostic index of active demyelination: myelin basic protein in CSF . Ann Neurol8: 25-31 .
21.
Michetti F , Massaro AR , Russo G , Rigon G. (1980) S-100 antigen in CSF as a possible index of cell injury in the nervous system . J Neurol Sci60: 443-451 .
22.
Sindic Ch JMet al. (1982) Assessment of damage to the central nervous system by determination of S-100 protein in the CSF . J Neurol Neurosurg Psychiat45: 1130-1135 .
23.
Mokuno Ket al. (1983) Neuron-specific enolase and S- 100 protein levels in CSF of patients with various neurological diseases . J Neurol Sci60: 443-451 .
24.
Postert THet al. (1996) S-100 protein and neuron-specific enolase in serum and CSF of patients with multiple sclerosis in comparison to controls . Europ J Neurol3 (S4): 45-46 .
25.
Albrechtsen M , Massaro AR , Bock E. (1985) Enzyme-linked immunosorbent assay for the human GFAP using mouse monoclonal antibody . J Neurochem44: 560-566 .
26.
Rosengren L , Karlsson E-J. (1996) Glial and neuronal intermediate proteins as tools in CSF diagnostics . J Neurochem66(S2): s26-s26 and s28-s28 .
27.
Bracci Laudiero Let al. (1992) Multiple sclerosis patients express increased levels of b-nerve growth factor in cerebrospinal fluid . Neurosci Letters147: 9-12 .
28.
Massaro ARet al. (1994) Nerve growth factor (NGF) in cerebrospinal fluid from patients with various neurological disorders . It J Neurol Sci15: 105-108 .
29.
Gallo P , Tavolato B. (1996) Cytokines in multiple sclerosis cerebrospinal fluid and serum. In: Thompson EJ , Troiano M , Livrea P , eds. Cerebrospinal Fluid Analysis in Multiple Sclerosis. Milano: Springer-Verlag Italia pp. 93-104.
30.
Andersson Met al. (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report . J Neurol Neurosurg Psychiat57: 897-902 .
